A neuroattenuated ICP34.5-deficient herpes simplex virus type 1 replicates in ependymal cells of the murine central nervous system
S Kesari, TM Lasner, KR Balsara, BP Randazzo, VM Lee, JQ Trojanowski and NW Fraser The Wistar Institute, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA. Herpes simplex virus type 1 (HSV-1) variant 1716 is deleted in the gene en...
Gespeichert in:
Veröffentlicht in: | Journal of general virology 1998-03, Vol.79 (3), p.525-536 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | S Kesari, TM Lasner, KR Balsara, BP Randazzo, VM Lee, JQ Trojanowski and NW Fraser
The Wistar Institute, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104, USA.
Herpes simplex virus type 1 (HSV-1) variant 1716 is deleted in the gene
encoding ICP34.5 and is neuroattenuated after intracranial inoculation of
mice. Although the mechanism of attenuation is unclear, this property has
been exploited to eliminate experimental brain tumours. Previously, it was
shown that infectious 1716 was recoverable for up to 3 days after
intracranial inoculation suggesting that there may be limited replication
in the central nervous system (CNS). Here it is demonstrated that 1716
replicates in specific cell types (predominantly CNS ependymal cells) of
BALB/c mice, using immunohistochemical, immunofluorescence, in situ
hybridization and virus titration studies. While 1716-infected mice
exhibited no overt signs of encephalitis, histological analysis showed a
persistent loss of the ependymal lining. Thus, although ICP34.5-deficient
viruses are neuroattenuated, they do retain the ability to replicate in and
destroy the ependyma of the murine CNS. A detailed understanding of the
mechanism(s) of neuroattenuation and limited replication could lead to the
rational design of safe HSV vectors for cancer and gene therapy in the CNS. |
---|---|
ISSN: | 0022-1317 1465-2099 |
DOI: | 10.1099/0022-1317-79-3-525 |